Epstein-Barr virus (EBV), a member of the
Herpesviridae family, is associated with lymphoid malignant neoplasms and epithelial carcinogenesis, including gastric cancer (GC).
1 Though EBV-associated GC (EBV-GC) accounts for approximately 9% of all GCs,
2-4 EBV-GC is 1 of the 4 major molecular subtypes of GC and shows clinical characteristics distinct from non–EBV-GC, such as a higher incidence in men and in the proximal location of the stomach, a lower incidence of lymph node metastasis, and a better prognosis.
2-11 It recently has been established that programmed cell death 1 ligand 1 expression is high in EBV-GC, 1 of the target cancers for immune checkpoint inhibitor therapy, along with microsatellite instability (MSI)–high GC.
12